在泛癌瘤中替代性延长端粒的代谢途径
Isaac Armendáriz-Castillo1,2, Jennyfer García-Cárdenas1, Pamela Espinosa3
1Laboratorio de Ciencia de Datos Biomédicos, Facultad de Ciencias Médicas de la Salud y de la Vida, Universidad Internacional del Ecuador, Quito, Ecuador.
PloS one
|February 21, 2025
概括
替代延长端粒 (ALT) 是癌症生存机制,与特定的代谢途径有关. 这项研究确定了关键的代谢标和FDA批准的药物用于ALT阳性瘤.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 癌症生物学 癌症生物学
背景情况:
- 端粒的替代延长 (ALT) 是一个关键的机制,使得攻击性癌症能够逃避衰老.
- ALT赋予恶性瘤和对标准癌症治疗的抵抗力.
- 之前的研究通过多原子数据集成确定了参与ALT途径的关键蛋白质.
研究的目的:
- 通过将代谢组数据与先前的蛋白质组发现相结合,在ALT阳性瘤中确定可向的代谢途径.
- 阐明代谢产物与ALT相关蛋白之间的复杂相互作用.
- 发现ALT驱动癌症的潜在治疗策略.
主要方法:
- 将新陈代谢数据集与有关ALT相关蛋白质的现有多原子数据集集成.
- 网络分析以探索代谢物和蛋白质之间的相互作用.
- 优先考虑FDA批准的针对已识别的代谢途径的药物.
主要成果:
- 鉴定了与42种代谢产物相互作用的39种ALT相关蛋白质.
- 发现一个复杂的网络,连接代谢物,ALT蛋白和潜在的泛癌瘤基因.
- 精确确定了三个关键的代谢途径: purin代谢,cysteine/methionine代谢和尼古丁酸/尼古丁胺胺代谢.
结论:
- 代谢重编程,特别是涉及 purin,cysteine/methionine 和 nicotinate/nicotinamide 途径,是 ALT 机制的组成部分.
- 针对纯素代谢的FDA批准的药物 (阿扎西奥普林,提奥瓜宁,默卡普托普林) 在治疗ALT阳性癌症方面表现有前途.
- 需要进一步的实验验证,以确认这些代谢标和治疗策略.
相关概念视频
Replicative Cell Senescence
3.6K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.6K
Telomeres and Telomerase
23.0K
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded...
23.0K
Replication in Eukaryotes
12.9K
In eukaryotic cells, DNA replication is highly conserved and tightly regulated. Multiple linear chromosomes must be duplicated with high fidelity before cell division, so there are many proteins that fulfill specialized roles in the replication process. Replication occurs in three phases: initiation, elongation, and termination, and ends with two complete sets of chromosomes in the nucleus.
Many Proteins Orchestrate Replication at the Origin
Eukaryotic replication follows many of the same...
Many Proteins Orchestrate Replication at the Origin
Eukaryotic replication follows many of the same...
12.9K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Long-patch Base Excision Repair
6.9K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
6.9K


